Myostatin has been an attractive target for treating musculoskeletal dysplasias associated with inferior muscle and bone function as seen in osteoporosis, OI, and DMD since myostatin regulates muscle metabolism and homeostasis. The gene discussed is MSTN; the disease is osteogenesis imperfecta.